Physician profile

Beverly Green

Dentist · Tamarac, FL

NPI 1558704122

$3,304.37

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$83.62

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Patterson Companies, INC. $2,694.00 2020
Dentsply LLC $185.60 2021
Align Technology, INC. $125.25 2020-2021
Dentsply Sirona INC $86.02 2019-2021
Dentsply Ih INC. $69.65 2019
Thommen Medical USA, LLC $60.31 2023-2024
Orapharma, A Division of Bausch Health US, LLC $37.43 2020-2024 Arestin
Crosstex International INC. $23.19 2019
Dentsply Sirona Orthodontics INC $12.01 2019
3m Company $10.91 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Beverly Green

$3,304.37

in general payments reported 2019-2025

Years
2019-2024
Top company
Patterson Companies, INC.

https://glasscript.com/doctor/1062474/beverly-green

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.